Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A promising combo for hard-to-treat lung cancer. Updated data from the phase 1 KANDLELIT-001 trial show that first-line calderasib plus pembrolizumab achieved a 71% response rate and a median progression-free survival of nearly 29 months in patients with KRAS G12C–mutated metastatic NSCLC. Results were even stronger in patients with higher PD-L1 expression, supporting two ongoing phase 3 trials.
A promising combo for hard-to-treat lung cancer
Updated data from the phase 1 KANDLELIT-001 trial, presented at the 2026 ESMO Congress, show that first-line calderasib — an oral KRAS G12C inhibitor — combined with pembrolizumab delivered durable and clinically meaningful responses in patients with KRAS G12C–mutated metastatic non-small cell lung cancer (NSCLC). Among patients with a PD-L1 tumor proportion score (TPS) of 1% or higher, the objective response rate (ORR) hit 71% and median progression-free survival (PFS) reached 28.8 months.
PD-L1 expression clearly mattered: patients with a TPS of 50% or higher saw an even higher ORR of 84% and a median PFS of 34.4 months. By comparison, calderasib alone in previously treated patients yielded a 35% ORR and an 8.3-month median PFS — underscoring the added benefit of the immunotherapy combination in the frontline setting.
By the Numbers
Why it matters: KRAS G12C mutations are among the most common oncogenic drivers in NSCLC, yet historically difficult to target. These results support enrollment in two ongoing phase 3 trials (KANDLELIT-004 and KANDLELIT-007), potentially paving the way for a new frontline standard of care.